On the heels of an FDA panel’s recent approval of Exact Sciences’ cancer-screening test Cologuard, the company has signaled that it may sell stock or debt securities in the near future. The Madison company filed with the SEC to offer $125 million in shares of common stock, though no specific date was set.
Exact Sciences files for stock offering
Get Our Email Newsletter
The companies, people and issues shaping business in Madison and the Capital Region.
